2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research 2021, 27: 4757-4767. PMID: 34140403, PMCID: PMC9236708, DOI: 10.1158/1078-0432.ccr-21-0903.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1Non-small cell lung cancerCell lung cancerRenal cell carcinomaPD-L1Lung cancerDisease progressionCommon treatment-related adverse eventsPD-1/PD-L1 inhibitorsTreatment-related adverse eventsPhase 2 doseSubstantial clinical challengeUnconfirmed partial responseDose-limiting toxicityPD-L1 inhibitorsPhase I trialDose-escalation designPro-inflammatory cytokinesMultiple tumor typesAsymptomatic elevationStable diseaseIntolerable toxicityAdverse eventsMedian durationPartial response
2016
The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort
Stahl M, Podoltsev N, DeVeaux M, Perreault S, Itzykson R, Ritchie E, Sekeres M, Fathi A, Komrokji R, Bhatt V, Al-Kali A, Cluzeau T, Santini V, Brunner A, Roboz G, Fenaux P, Litzow M, Vey N, Verma V, Germing U, Fernández P, Zelterman D, Kim T, Prebet T, Gore S, Zeidan A. The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. Blood 2016, 128: 1063. DOI: 10.1182/blood.v128.22.1063.1063.Peer-Reviewed Original ResearchMultivariable logistic regression modelRR-AMLMinority of patientsOverall survivalPrior linesHypomethylating agentHMA therapyMedian numberLogistic regression modelsChromosome 7 abnormalitiesStable diseaseBlast percentageHematologic improvementProgressive diseaseHazard ratioClinical outcomesSpeakers bureauMultivariable Cox proportional hazards modelsPeripheral blood blast percentageRefractory acute myeloid leukemiaAllogeneic stem cell transplantationInternational Working Group criteriaWhite blood cell countCox proportional hazards modelBM blast percentage
2011
A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome.
Mehnert J, Mortazavi A, Stein M, Donadio A, Zelterman D, McDonough J, Rowen E, Hoimes C, Gibney G, Kelly W. A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Journal Of Clinical Oncology 2011, 29: 278-278. DOI: 10.1200/jco.2011.29.7_suppl.278.Peer-Reviewed Original ResearchTransitional cell carcinomaAdvanced transitional cell carcinomaPR/CRDose reductionOral tyrosine kinase inhibitorECOG PS 0Grade 3/4 neutropeniaHand-foot syndromePhase II trialProgression-free intervalMedian age 64Tyrosine kinase inhibitorsAnti-angiogenic propertiesECOG 0Evaluable diseaseMaintenance SNeutropenic feverNonhematologic toxicityHematologic toxicityMaintenance therapyPrimary endpointSecondary endpointsStable diseaseII trialPS 0
2006
Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer
Roy S, Russo S, Black G, Eloubeidi M, Steg A, Zelterman D, Johnson M, Diasio R, Saif M. Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer. Journal Of Clinical Oncology 2006, 24: 14001-14001. DOI: 10.1200/jco.2006.24.18_suppl.14001.Peer-Reviewed Original ResearchPhase II studyLA pancreatic cancerEfficacy of capecitabinePancreatic cancerII studyTNF-alphaThymidine phosphorylaseGI bleedingDose reductionSix-month survival ratesTP/DPD ratioTNF-alpha mRNA levelsPhase IActivity of capecitabineAdvanced pancreatic cancerGrade 1 anemiaGrade 1 thrombocytopeniaNausea/vomitingPts underwent surgeryEffect of XRTConcurrent XRTStable diseaseUnderwent surgeryMedian survivalPartial response